Alteriry Therapeutics Ltd Sponsored ADR ATHE 深 沪

美股大行评级 | Bernstein上调闪迪目标价从1700美元升至3000美元；大摩上调谷歌-A目标价从375美元升至415美元

今日重点评级关注：Citizens：维持DBV Technologies"跑赢大市"评级，目标价从47美元升至55美元；康托·菲茨杰拉德：维持BioCryst制药"超配"评级，目标价从27美元升至29美元

07-01 10:40

Jones Trading Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $16

Jones Trading analyst Debanjana Chatterjee initiates coverage on Alterity Therapeutics (NASDAQ:ATHE) with a Buy rating and announces Price Target of $16.

06-30 21:21

Alterity Therapeutics shares are trading higher after the company announced the outcome of its End-of-Phase 2 meeting with the FDA, agreeing on key elements of the proposed Phase 3 design, including study population, dosing regimen, and treatment duration.

Alterity Therapeutics shares are trading higher after the company announced the...

06-09 22:11

Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy

Alterity Therapeutics announced a successful End-of-Phase 2 meeting with the FDA, aligning on key elements for the Phase 3 program of ATH434 for Multiple System Atrophy (MSA). The FDA agreed on the Phase 3 trial design, including the 50mg dose, study population, and primary endpoint of the 11-item UMSARS Part I. ATH434 demonstrated a 48% slowing of disease progression vs placebo in Phase 2. The pivotal Phase 3 trial, expected to start by year-end...

06-09 11:05

Alterity Therapeutics Presents On Multiple System Atrophy Program Including Its Novel Imaging And Biomarker Approach, Phase 2 Data, And Current Plans To Advance ATH434 Into Phase 3 Clinical Development.

"These data continue to strengthen the evidence that ATH434 has the potential to be the first disease-modifying treatment for MSA, a rare and devastating disease with no approved therapy," said David Stamler, M.D., CEO

05-19 19:31

Alterity Therapeutics Showcases MSA Program Ahead of Phase 3 Push

Alterity Therapeutics ( ($AU:ATH) ) has shared an announcement. Alterity Therap...

05-07 09:42

Alterity Therapeutics Receives Positive FDA Feedback Following A Type C Meeting Regarding Its Planned Phase 3 Development Program For ATH434 In Multiple System Atrophy, A Rare, Rapidly Progressive Neurodegenerative Disease With No Approved Disease-Modifying Treatments

This second Type C Meeting builds on Alterity's recent regulatory interactions with the FDA and represents a further step towards readiness for the planned Phase 3 pivotal trial in MSA. Alterity received written feedback

04-27 19:28

Alterity to Spotlight ATH434 MSA Data in Late-Breaker at AAN Meeting

Alterity Therapeutics ( ($AU:ATH) ) has shared an announcement. Alterity Therap...

04-16 10:42

Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy

04-15 11:25

Alterity Flags Risks Around Forward‑Looking Corporate Outlook

The latest announcement is out from Alterity Therapeutics ( ($AU:ATH) ). Alteri...

04-01 13:28